Martingale Asset Management L P Has $17.10 Million Stock Holdings in Amgen Inc. $AMGN

Martingale Asset Management L P cut its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 9.2% during the third quarter, Holdings Channel.com reports. The fund owned 60,602 shares of the medical research company’s stock after selling 6,168 shares during the period. Martingale Asset Management L P’s holdings in Amgen were worth $17,102,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Evelyn Partners Investment Management LLP acquired a new stake in Amgen in the second quarter valued at $32,000. Howard Hughes Medical Institute bought a new stake in shares of Amgen during the second quarter valued at about $32,000. Cloud Capital Management LLC acquired a new position in shares of Amgen during the third quarter valued at $34,000. AXS Investments LLC bought a new stake in Amgen during the 3rd quarter worth approximately $42,000. Finally, Winnow Wealth LLC purchased a new stake in shares of Amgen in the 3rd quarter valued at $47,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: MariTide and osteoporosis drug sales cited as a key driver of recent investor enthusiasm; analysts/coverage note product momentum that helped push earlier gains. Amgen: MariTide And Osteoporosis Sales Fuel The Rally
• Positive Sentiment: Operational/production support: Rapid Micro Biosystems reported that Amgen expanded a global Growth Direct system rollout (multi‑system order), signaling investments in manufacturing capacity and process efficiency. Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
• Positive Sentiment: Institutional buying/positioning: Amgen is highlighted as a holding in a large income fund, reflecting demand from dividend/income managers seeking defensive, high‑yield large caps. Starbucks, Amgen, and CVS Help This Income Fund Shine
• Positive Sentiment: Macro/sector support: Prominent market commentators have endorsed large‑cap biotech as resilient growth plays, which supports longer‑term investor interest. Josh Brown: Biotech growth stocks immune to disruption risk
• Neutral Sentiment: Company presentation: A recent Leerink Global Healthcare conference transcript provides updated management commentary — useful for gauging near‑term guidance and pipeline cadence but not an immediate catalyst by itself. Amgen Inc. (AMGN) Presents at Leerink Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Valuation discussion: Coverage pieces assessing whether AMGN is mispriced highlight mixed returns vs. peers — useful context for investors but not a direct price mover. Assessing Whether Amgen (AMGN) Shares Look Mispriced After Recent Mixed Returns
• Neutral Sentiment: Short‑interest data appears to contain errors (reports show zero shares/NaN changes and a 0.0 days-to-cover figure); there’s no clear evidence of meaningful short pressure at present.
• Negative Sentiment: Analyst stance: Jefferies initiated coverage with a Hold recommendation, which can cap momentum relative to a Buy/Outperform narrative and may contribute to near‑term selling pressure. Jefferies initiates coverage of Amgen (AMGN) with hold recommendation

Wall Street Analyst Weigh In

Several equities research analysts recently commented on AMGN shares. UBS Group raised their target price on Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a report on Monday, January 26th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research report on Thursday, February 5th. Sanford C. Bernstein downgraded shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective for the company. in a report on Tuesday, January 20th. Daiwa Securities Group upped their price target on Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 10th. Finally, TD Cowen reissued a “buy” rating on shares of Amgen in a report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $354.00.

Amgen Stock Performance

NASDAQ:AMGN opened at $367.79 on Friday. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29. The stock has a 50-day simple moving average of $356.96 and a two-hundred day simple moving average of $324.63. The firm has a market capitalization of $198.26 billion, a PE ratio of 25.85, a P/E/G ratio of 3.75 and a beta of 0.45. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same quarter in the previous year, the company earned $5.31 EPS. Amgen’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.7%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is presently 70.84%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.